ZIOPHARM Oncology Statistics Share Statistics ZIOPHARM Oncology has 240.41M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 240.41M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) n/a Shares Floating n/a Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 35.28M, so 0% of the outstanding
shares have been sold short.
Short Interest 35.28M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 17.93
Valuation Ratios The PE ratio is -6.61 and the forward
PE ratio is null.
ZIOPHARM Oncology's PEG ratio is
0.14.
PE Ratio -6.61 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 4.26 P/FCF Ratio -7.91 PEG Ratio 0.14
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ZIOPHARM Oncology.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.11,
with a Debt / Equity ratio of 0.04.
Current Ratio 7.11 Quick Ratio 7.11 Debt / Equity 0.04 Debt / EBITDA -0.06 Debt / FCF -0.07 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-776.47K Employee Count 103 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0.5% in the
last 52 weeks. The beta is 1.69, so ZIOPHARM Oncology's
price volatility has been higher than the market average.
Beta 1.69 52-Week Price Change 0.5% 50-Day Moving Average n/a 200-Day Moving Average n/a Relative Strength Index (RSI) 35.3 Average Volume (20 Days) 2,362,949
Income Statement
Revenue n/a Gross Profit n/a Operating Income -79.98M Net Income -79.98M EBITDA -78.85M EBIT -79.98M Earnings Per Share (EPS) -0.38
Full Income Statement Balance Sheet The company has 115.07M in cash and 4.81M in
debt, giving a net cash position of 110.25M.
Cash & Cash Equivalents 115.07M Total Debt 4.81M Net Cash 110.25M Retained Earnings -764.1M Total Assets 113.76M Working Capital 68.38M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -57.01M
and capital expenditures -9.78M, giving a free cash flow of -66.79M.
Operating Cash Flow -57.01M Capital Expenditures -9.78M Free Cash Flow -66.79M FCF Per Share -0.32
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ZIOP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ZIOP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 24, 2005. It was a
backward
split with a ratio of 1:40.
Last Split Date Aug 24, 2005 Split Type backward Split Ratio 1:40
Scores Altman Z-Score -9.33 Piotroski F-Score 3
